These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 31258919)

  • 1. Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial.
    Celli BR; Anderson JA; Brook R; Calverley P; Cowans NJ; Crim C; Dixon I; Kim V; Martinez FJ; Morris A; Newby DE; Yates J; Vestbo J
    BMJ Open Respir Res; 2019; 6(1):e000431. PubMed ID: 31258919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD.
    Bhatt SP; Dransfield MT; Cockcroft JR; Wang-Jairaj J; Midwinter DA; Rubin DB; Scott-Wilson CA; Crim C
    Int J Chron Obstruct Pulmon Dis; 2017; 12():351-365. PubMed ID: 28176907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk.
    Calverley PMA; Anderson JA; Brook RD; Crim C; Gallot N; Kilbride S; Martinez FJ; Yates J; Newby DE; Vestbo J; Wise R; Celli BR;
    Am J Respir Crit Care Med; 2018 Jan; 197(1):47-55. PubMed ID: 28737971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
    Siler TM; Nagai A; Scott-Wilson CA; Midwinter DA; Crim C
    Respir Med; 2017 Feb; 123():8-17. PubMed ID: 28137501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.
    Vestbo J; Anderson JA; Brook RD; Calverley PM; Celli BR; Crim C; Martinez F; Yates J; Newby DE;
    Lancet; 2016 Apr; 387(10030):1817-26. PubMed ID: 27203508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial.
    Hanania NA; Mannino DM; Criner GJ; Dransfield MT; Han MK; Jones CE; Kilbride S; Lomas DA; Martin N; Martinez FJ; Singh D; Wise RA; Halpin DMG; Lima R; Lipson DA
    Chest; 2021 Mar; 159(3):985-995. PubMed ID: 33031829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction.
    Martinez FJ; Vestbo J; Anderson JA; Brook RD; Celli BR; Cowans NJ; Crim C; Dransfield M; Kilbride S; Yates J; Newby DE; Niewoehner D; Calverley PM;
    Am J Respir Crit Care Med; 2017 Apr; 195(7):881-888. PubMed ID: 27767328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk.
    Brook RD; Anderson JA; Calverley PM; Celli BR; Crim C; Denvir MA; Magder S; Martinez FJ; Rajagopalan S; Vestbo J; Yates J; Newby DE;
    Heart; 2017 Oct; 103(19):1536-1542. PubMed ID: 28416587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.
    Pascoe S; Locantore N; Dransfield MT; Barnes NC; Pavord ID
    Lancet Respir Med; 2015 Jun; 3(6):435-42. PubMed ID: 25878028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial.
    Crim C; Calverley PMA; Anderson JA; Holmes AP; Kilbride S; Martinez FJ; Brook RD; Newby DE; Yates JC; Celli BR; Vestbo J;
    Respir Med; 2017 Oct; 131():27-34. PubMed ID: 28947039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review with meta-analysis of fluticasone furoate/vilanterol combination for the treatment of stable COPD.
    Rodrigo GJ; Neffen H
    Pulm Pharmacol Ther; 2017 Feb; 42():1-6. PubMed ID: 27864038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of COPD-related outcomes in patients initiating a once daily or twice daily ICS/LABA.
    Stanford RH; Parker ED; Reinsch TK; Buikema AR; Blauer-Peterson C
    Respir Med; 2019 Apr; 150():1-7. PubMed ID: 30961933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
    Kerwin EM; Scott-Wilson C; Sanford L; Rennard S; Agusti A; Barnes N; Crim C
    Respir Med; 2013 Apr; 107(4):560-9. PubMed ID: 23352226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
    Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM
    Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the China cohort in the IMPACT trial.
    Zheng J; Zhong N; Wang C; Wei LP; Zhou XD; Zhao L; Dong Yuan Y; He B; Wu B; Du X; Song J; Lipson DA
    Curr Med Res Opin; 2021 Jan; 37(1):145-155. PubMed ID: 33124900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-Life Clinical and Functional Effects of Fluticasone Furoate/Umeclidinium/Vilanterol-Combined Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease.
    Pelaia C; Procopio G; Deodato MR; Florio O; Maglio A; Sciacqua A; Vatrella A; Pelaia G
    Respiration; 2021; 100(2):127-134. PubMed ID: 33302284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of fluticasone furoate/vilanterol (50/25 mcg; 100/25 mcg; 200/25 mcg) in Asian patients with chronic obstructive pulmonary disease: a randomized placebo-controlled trial.
    Zheng J; de Guia T; Wang-Jairaj J; Newlands AH; Wang C; Crim C; Zhong N
    Curr Med Res Opin; 2015 Jun; 31(6):1191-200. PubMed ID: 25830381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised, double-blind, placebo-controlled, cross-over single dose study of the bronchodilator duration of action of combination fluticasone furoate/vilanterol inhaler in adult asthma.
    Braithwaite I; Williams M; Power S; Pilcher J; Weatherall M; Baines A; Moynihan J; Kempsford R; Beasley R;
    Respir Med; 2016 Oct; 119():115-121. PubMed ID: 27692131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD.
    Agustí A; de Teresa L; De Backer W; Zvarich MT; Locantore N; Barnes N; Bourbeau J; Crim C
    Eur Respir J; 2014 Mar; 43(3):763-72. PubMed ID: 24114969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.